ReShape Lifesciences Inc (NASDAQ:RSLS) shares, rose in value on Wednesday, April 16, with the stock price down by -4.45% to the previous day’s close as strong demand from buyers drove the stock to $0.36.
Actively observing the price movement in the last trading, the stock closed the session at $0.38, falling within a range of $0.3415 and $0.3781. The value of beta (5-year monthly) was 1.925. Referring to stock’s 52-week performance, its high was $29.00, and the low was $0.30. On the whole, RSLS has fluctuated by -43.25% over the past month.
With the market capitalization of ReShape Lifesciences Inc currently standing at about $4.09 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-03.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RSLS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RSLS currently trading nearly -30.12% and -66.13% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.28, while the 7-day volatility ratio is showing 19.12% which for the 30-day chart, stands at 39.84%. Furthermore, ReShape Lifesciences Inc (RSLS)’s beta value is 1.41, and its average true range (ATR) is 0.25.
A comparison of ReShape Lifesciences Inc (RSLS) with its peers suggests the former has fared considerably weaker in the market. RSLS showed an intraday change of -4.45% in last session, and over the past year, it shrunk by -96.19%%.
Data on historical trading for ReShape Lifesciences Inc (NASDAQ:RSLS) indicates that the trading volumes over the past 10 days have averaged 39.31 and over the past 3 months, they’ve averaged 12.81 million. According to company’s latest data on outstanding shares, there are 11.28 million shares outstanding.
Nearly 18.08% of ReShape Lifesciences Inc’s shares belong to company insiders and institutional investors own 0.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.69 million shares as on 2025-03-31, resulting in a short ratio of 1.14. According to the data, the short interest in ReShape Lifesciences Inc (RSLS) stood at 2084.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.47 million. The stock has fallen by -91.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RSLS stock heading into the next quarter.
